Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.3752W HIGH $8.30
Volume
119.84 K
Value Traded
210.50 K
Short % Float
0.52%
Days to Cover
5.1
+2.52%Week
-6.59%1 Month
-21.26%3 Month
-60.24%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
36.95 M
EPS (TTM)
-0.61
P/E Ratio
-
Ent. Value
91.32 M
Total Shares
22.67 M
Float Shares
14.53 M
Insiders
16.12%
Institutions
9.94%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
BHST Catalyst Timeline
Dated clinical, regulatory and corporate events for BioHarvest Sciences Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for BioHarvest Sciences Inc.
145Total events
9Upcoming
16Tier-1 (high impact)
2023 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Manufacturing MilestoneCMC / Inspection
Olive Cell reaches commercial readiness with GMP manufacturing established
▲Platform ValidationPreclinical
Botanical Synthesis platform demonstrated capability to produce targeted next-generation sweetening solution
▲Corporate ApprovalCorporate
Board of Directors authorized normal course issuer bid (NCIB) share repurchase program
●R&D DayPresentation
Presenting at Canaccord Growth Conference and H.C. Wainwright 28th Annual Global Investment Conference
●R&D DayPresentation
CEO Zaki Rakib to present at Canaccord Genuity 46th Annual Growth Conference
▲Partnership / LicenseCorporate
Exclusive manufacturing and supply agreement with UAE fragrance partner extended through 2027-2028
▲Partnership / LicenseCorporate
Exclusive manufacturing and supply agreement for rare plant-based fragrance ingredient with UAE-based customer
▲Grant / FundingCorporate
$1.4M Grant awarded from Israel Innovation Authority for AI-driven R&D and manufacturing automation
◆Oral PresentationPresentation
BioHarvest Sciences to present at 2026 BIO International Convention
▲Preclinical PoCPreclinical
Successful completion of Stage 1 development of saffron composition
nutraceutical and culinary applicationssource ↗
▲Development Candidate NominationPreclinical
Successful completion of Stage 1 development of saffron composition, establishing stable saffron cell bank
saffron composition for nutraceutical and culinary applicationssource ↗
▲Manufacturing MilestoneCMC / Inspection
Advancement to Stage 2 of development agreement valued at $1.125 million
saffron composition for nutraceutical and culinary applicationssource ↗
▲Partnership / LicenseCorporate
Signed $1.2M CDMO Stage 2 contract for development of rare fragrance
rare fragrance raw materialsource ↗
▲Partnership / LicenseCorporate
Saffron development program advanced to Stage 2 with $1.125 million contract with SaffronTech
▲Milestone PaymentCorporate
Completed Stage 1 of saffron development program with Saffron Tech
◆Management ChangeCorporate
Zaki Rakib assumes role of CEO; Ilan Sobel transitions to Board of Directors
◆Quarterly UpdateCorporate
Fourth Quarter and Full Year 2025 Financial Results and Conference Call
▲Manufacturing MilestoneCMC / Inspection
Stage 1 completed: stable cell bank produced
rare fragrance raw materialsource ↗
▲Milestone PaymentCorporate
Completed Stage 1 of multi-stage development program for rare fragrance plant
▲Preclinical PoCPreclinical
Successful Stage 1 completion creating stable cell culture for rare endangered fragrance plant
▲Development Candidate NominationPreclinical
Successful completion of Stage 1 development of rare botanical fragrance ingredient
▼Runway Guidance UpdateCorporate
Full-year 2026 revenue guidance revised to $32-$33.5M and Adjusted EBITDA loss of $5.5-$7.5M
▲Other Regulator MilestoneEx-US Regulatory
Awarded $1.6M grant from Israeli Innovation Authority for second-generation Botanical Synthesis platform
◆Oral PresentationPresentation
BioHarvest Sciences to attend Craig-Hallum 16th Annual Alpha Select Conference
▼Equity OfferingCorporate
Priced underwritten public offering of 2,485,000 shares at $7.00 per share
▼Equity OfferingCorporate
Announced intention to offer shares in underwritten public offering
▲Product LaunchPost-Market
VINIA Blood Flow Hydration product launched in end November 2025
blood flow hydrationsource ↗
▼Equity OfferingCorporate
Oversubscribed institutional equity financing completed in November 2025
▲Partnership / LicenseCorporate
Announced contract with Saffron Tech for 'super' saffron-derived compound (October 2025)
●Quarterly UpdateCorporate
Q4 2025 revenue guidance $9-$9.5M, adjusted EBITDA range ($0.6M)-$0.0M
▲Product LaunchPost-Market
Launching VINIA BloodFlow Hydration Solution in October 2025
electrolyte hydrationsource ↗
▲Equity OfferingCorporate
Completed accelerated warrant exercises and debt-to-equity conversions raising $10.9M gross proceeds and reducing debt by $3.8M
Past FDA Catalysts and PDUFA Decisions
How BHST actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every BHST program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in BHST
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BHST for Q2 2026. | ||||
Ownership Trends
BHST Short Interest
Shares sold short, counted twice a month.
0.52%
Short % of Float
of tradable shares sold short
75.6K
Shares Sold Short
-16.2% vs prior count
5.1 High
Days to Cover
trading days of normal volume to buy every short share back
14.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BHST ranks across every disease it competes in
Competitive Position is a premium feature
See how BHST ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBHST News
-BHST
Nov 12, 2026▼ -6.9%on this news
BioHarvest Reports Third Quarter 2026 Financial Results and Provides Business Update
BioHarvest Sciences reported Q3 2026 revenue of $7.9 million, down from $9.1 million a year prior. The company is focusing on cash preservation and selective growth strategies for its VINIA product line. An exclusive manufacturing agreement for a high-value fragrance ingredient was signed, with production expected to begin in early 2027. The company anticipates improved revenue growth starting in Q1 2027.
Read more →-BHST
Oct 29, 2026▼ -5.7%on this news
BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026
BioHarvest Sciences Inc. will report its Q3 2026 financial results on November 12, 2026. The company plans to host a conference call at 8:00 AM ET to discuss the results and its strategic transformation. CEO Zaki Rakib will highlight developments that could enhance long-term revenue growth.
Read more →-BHST
Oct 13, 2026▲ +12.3%on this news
BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity
BioHarvest Sciences Inc. announced that its proprietary Olive Cell composition has achieved commercial readiness, completing the necessary GRAS process and large-scale manufacturing. The Olive Cell, derived from olive fruit, demonstrates promising preclinical activity in liver health models. This milestone opens new licensing opportunities through BioHarvest's CDMO business.
Read more →-BHST
Oct 8, 2026Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme
Tate & Lyle and BioHarvest Sciences have achieved a significant milestone in their next-generation sweetener development program. BioHarvest's Botanical Synthesis platform has proven capable of producing a targeted sweetening solution, encouraging both companies. This collaboration aims to provide innovative sweetening solutions that reduce sugar and calorie content while maintaining taste.
Read more →-BHST
Sep 29, 2026BioHarvest Sciences Announces Share Repurchase Program
BioHarvest Sciences Inc. has announced a share repurchase program authorized by its Board of Directors. The program allows the company to buy back up to 5% of its outstanding shares, reflecting the belief that the current market price does not represent the company's true value. CEO Dr. Zaki Rakib emphasized the company's evolution into a technology-driven firm with multiple growth opportunities.
Read more →-BHST
Sep 15, 2026BioHarvest Advances Botanical Synthesis Leadership as VINIA Daily Chews Unlock More Value from Its First Consumer Product
BioHarvest Sciences Inc. has launched VINIA Daily Chews, expanding its product line and demonstrating its leadership in Botanical Synthesis. This new format aims to reach a broader demographic and enhance customer engagement. The chewable supplements are designed to fit into daily habits while maintaining the same dosage as existing products. Early feedback suggests strong market interest, but uncertainties remain regarding consumer acceptance.
Read more →-BHST
Sep 14, 2026BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
BioHarvest Sciences Inc. announced that CEO Zaki Rakib will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City. The conference will take place from September 14-16, 2026, where Rakib will discuss recent advancements and opportunities in their botanical synthesis technology. The event includes both in-person and virtual participation options for investors.
Read more →-BHST
Sep 3, 2026▼ -5.3%on this news
BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
BioHarvest Sciences Inc. has announced its intention to dual-list its shares on the Tel Aviv Stock Exchange (TASE) alongside its existing Nasdaq listing. The shares are expected to begin trading on September 8, 2026. CEO Dr. Zaki Rakib highlighted the growth potential and connection with the Israeli investment community as key motivations for this move.
Read more →-BHST
Aug 11, 2026BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update
BioHarvest Sciences Inc. reported Q2 2026 revenues of $8.8 million, up 3.8% from the previous year. The company secured its first CDMO manufacturing agreement for a rare fragrance ingredient, expected to drive future growth. Despite the positive revenue growth, operating losses increased, highlighting ongoing challenges in profitability.
Read more →-BHST
Aug 11, 2026BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance
BioHarvest Sciences Inc. secured an exclusive manufacturing agreement for a rare fragrance plant, expected to generate $20-$30 million by 2028. The company will produce 20 metric tons of a valuable fragrance compound, leveraging its Botanical Synthesis technology. This move positions BioHarvest to enter the lucrative luxury fragrance market, which is projected to grow significantly.
Read more →-BHST
Jul 29, 2026▲ +7.6%on this news
BioHarvest Sciences to Present at the Canaccord Genuity 46th Annual Growth Conference
BioHarvest Sciences Inc. announced that CEO Zaki Rakib will present at the Canaccord Genuity 46th Annual Growth Conference from August 11-13, 2026, in Boston. The presentation is scheduled for August 12 at 1:00 p.m. ET. The conference aims to connect institutional investors with promising growth companies.
Read more →-BHST
Jun 18, 2026BioHarvest Sciences to Present at the 2026 BIO International Convention
BioHarvest Sciences Inc. will present its Botanical Synthesis platform at the BIO International Convention in San Diego from June 22-25, 2026. The presentation aims to demonstrate the technology's potential in producing pharmaceutical-grade plant-derived compounds. The event offers a platform for engaging with pharmaceutical organizations and exploring strategic collaborations.
Read more →-BHST
Jun 18, 2026DATED JUNE 18, 2026 News Release dated
BioHarvest Sciences Inc. announced its participation in the 2026 BIO International Convention to showcase its proprietary Botanical Synthesis platform. Scheduled for June 24, the presentation aims to attract strategic partnerships to exploit the technology's potential in drug discovery and pharmaceutical applications. The company highlights its expansive capabilities and recent initiatives, focusing on the long-term value for its shareholders. However, challenges such as uncertain future contracts and market acceptance remain as significant considerations.
Read more →-BHST
May 18, 2026TATE & LYLE EXPANDS COLLABORATION WITH BIOHARVEST SCIENCES TO ACCELERATE NEXT-GENERATION SWEETENER INNOVATION
BioHarvest Sciences has expanded its collaboration with Tate & Lyle to develop multiple plant-based sweeteners. This initiative aims to provide diverse sweetening solutions tailored to various food and beverage categories, enhancing consumer choice and supporting health goals. The partnership leverages BioHarvest's Botanical Synthesis technology to create sustainable, non-GMO ingredients.
Read more →-BHST
May 14, 2026Unaudited Interim Condensed Consolidated Financial Statements
BioHarvest Sciences Inc. released its unaudited interim consolidated financial statements for the three months ended March 31, 2026. The financial results show an increase in gross profit to $5,037 compared to $4,595 in the same quarter last year, although the net loss has risen to $2,641 from $2,338. Current liabilities have also increased, and the total assets declined from $47,665 to $45,558. The company continues developing its Botanical Synthesis technology, which aims to enhance production while minimizing negative environmental impacts.
Read more →-BHST
May 14, 2026BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
BioHarvest Sciences reported its first-quarter financial results for 2026, achieving an 8% increase in revenue year-over-year, totaling $8.5 million. Significant milestones were reached in the CDMO division, with a remarkable 135% growth in CDMO revenue. However, the company also reported an increased net loss of $2.6 million compared to $2.3 million from the previous year. The VINIA brand continues to thrive, boasting 90,000 active users and contributing significantly to the company's revenue.
Read more →-BHST
May 13, 2026BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications
BioHarvest Sciences has successfully completed Stage 1 of its saffron composition development, establishing a stable saffron cell bank in partnership with SaffronTech. This milestone allows for the advancement to Stage 2, focusing on generating biomass for pre-commercial testing. The project aims to address sustainability and supply chain challenges in saffron production, tapping into a significant market demand.
Read more →-BHST
May 12, 2026BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using its Proprietary Botanical Synthesis Platform
BioHarvest Sciences has signed a $1.2 million Stage 2 contract with an unnamed UAE investment firm to develop a rare fragrance using its proprietary Botanical Synthesis technology. Following a successful Stage 1, the company aims to produce enough material for commercial trials within 6-9 months, setting the stage for entry into the $23 billion premium fragrance market by late 2027. With continued investment in manufacturing capacities, BioHarvest is positioned to establish long-term royalty-driven revenue streams.
Read more →-BHST
May 11, 2026▼ -7.1%on this newsshared move
MATERIAL CHANGE REPORT DATED MAY 11, 2026 Material Change Report dated
BioHarvest Sciences Inc. has announced a leadership transition, appointing Dr. Zaki Rakib as the new CEO, replacing Ilan Sobel who will now serve on the Board of Directors. This shift aims to streamline operations in both the direct-to-consumer and CDMO sectors. Dr. Rakib's extensive experience and prior leadership role are expected to further propel the company's growth. Under Sobel, the company grew from a pre-revenue phase to generating approximately $35 million in revenue in 2025.
Read more →-BHST
Apr 30, 2026BioHarvest Sciences to Report First Quarter 2026 Financial Results on May 14, 2026
BioHarvest Sciences Inc. announced it will report its first quarter 2026 financial results on May 14, 2026. A conference call and webcast will occur at 8:00 a.m. Eastern Time, aimed at discussing results and providing business updates. The company specializes in its Botanical Synthesis technology, which allows it to develop plant-based compounds without cultivating the actual plants. Attendees are encouraged to register for the webcast ahead of time, and a recorded replay will be available afterward.
Read more →About BioHarvest Sciences Inc.
BIOPHARMAWATCH ELITE
Trade the next BHST catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime